-+ 0.00%
-+ 0.00%
-+ 0.00%

BRIEF-Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB

Reuters·09/29/2026 11:30:59

Please log in to view news